Friday, September 27, 2013 1:43:48 PM
I've been watching this one for a while and actually rode it from $1.50 to $1.70 earlier this year - I managed to get out just in time. I've been waiting on the sidelines till I thought it bottomed and I was able to get back in again at .30. I was trying to get filled at .29 for the past few days and finally caved.
I have no special knowledge and can't advise anyone on when to buy or sell, but my feeling is that we've hit bottom. When I sold at 1.70, there were a lot of hints of disaster to come and sure enough the news couldn't have been worse. My feeling is that we got the bad news out of the way, they've made significant changes to management, and this will start climbing on the run up to the next FDA approval date. What happens after that depends on the FDA outcome, but in the meantime I think there is some money to be made riding this from .30-.40. Just my humble opinion of course - do your own DD
I have no special knowledge and can't advise anyone on when to buy or sell, but my feeling is that we've hit bottom. When I sold at 1.70, there were a lot of hints of disaster to come and sure enough the news couldn't have been worse. My feeling is that we got the bad news out of the way, they've made significant changes to management, and this will start climbing on the run up to the next FDA approval date. What happens after that depends on the FDA outcome, but in the meantime I think there is some money to be made riding this from .30-.40. Just my humble opinion of course - do your own DD
Recent DCTH News
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
- Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call • Business Wire • 02/12/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:41:34 PM
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference • Business Wire • 01/27/2026 01:05:00 PM
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 01/21/2026 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 09:41:41 PM
- Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 01/09/2026 01:05:00 PM
- Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma • Business Wire • 12/31/2025 01:00:00 PM
